CODX vs CLOV

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus -84. 1% for Co-Diagnostics, Inc. (CODX). Analysts rate Co-Diagnostics, Inc. (CODX) a "Hold" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Clover Health Investments, Corp.

(CLOV) delivered a total return of -67. 3%, compared to -76. 3% for Co-Diagnostics, Inc. (CODX). Over 10 years, the gap is even starker: CODX returned -66. 8% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Co-Diagnostics, Inc.

(CODX) is the lower-risk stock at 1. 09β versus Clover Health Investments, Corp. 's 1. 22β — meaning CLOV is approximately 12% more volatile than CODX relative to the S&P 500.

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus -84. 1% for Co-Diagnostics, Inc. (CODX). On earnings-per-share growth, the picture is similar: Co-Diagnostics, Inc. grew EPS 5. 2% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, CLOV leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Clover Health Investments, Corp.

(CLOV) is the more profitable company, earning -4. 4% net margin versus -75. 3% for Co-Diagnostics, Inc. — meaning it keeps -4. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CLOV leads at -4. 4% versus -50. 3% for CODX. At the gross margin level — before operating expenses — CODX leads at 64. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CODX: 210.

9% to $6. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Co-Diagnostics, Inc.

(CODX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09)). Both have compounded well over 10 years (CODX: -66. 8%, CLOV: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CODX is a small-cap quality compounder stock; CLOV is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.